The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml solution, as well as a 120 mg/1.7 ml solution in a single-dose vial.

Reykjavik, Iceland Friday, March 21, 2025, 12:00 Hrs [IST] ...

Number 3: The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

ROCKVILLE, MD, USA I March 20, 2025 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and ...

Johnson & Johnson, facing potential drug import tariffs from the Trump administration, will invest over $55 billion in the ...

Here are four perfect high-yield dividend stock picks for investors looking to follow the lead of the top money managers on ...

Mr. Anurag Mantri, Executive Director & Group CFO of Jindal Stainless Limited has tendered his resignation from the services ...

SEATTLE, WA, USA I March 21, 2025 I Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating ...